Topical Infliximab in Eyes With Penetrating Keratoplasty

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

March 1, 2027

Study Completion Date

March 1, 2028

Conditions
Glaucoma Following Surgery
Interventions
DRUG

Topical infliximab

Infliximab eye drops (10mg/ml) administered four (4) times per day for three (3) months.

OTHER

No topical infliximab

No treatment with infliximab.

Trial Locations (1)

H2X 3E4

RECRUITING

Centre Hospitalier de l'Université de Montréal, Montreal

Sponsors
All Listed Sponsors
collaborator

Fonds de recherche en ophtalmologie de l'Université de Montréal

OTHER

collaborator

Maisonneuve-Rosemont Hospital

OTHER

collaborator

Niagara Health System

OTHER

collaborator

Prism Eye Institute

OTHER

collaborator

Ottawa Hospital Research Institute

OTHER

lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER